Cargando…

The cytokine interleukin-26 as a biomarker in pediatric asthma

In this pilot study, we examined associations between local interleukin (IL)-26, disease severity and biomarkers of Th2-mediated inflammation in a well-defined cohort of pediatric patients (14 years median age, 41 % females) with controlled (n = 28) or uncontrolled (n = 48) asthma. Sputum IL-26 prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Konradsen, Jon R., Nordlund, Björn, Levänen, Bettina, Hedlin, Gunilla, Linden, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815075/
https://www.ncbi.nlm.nih.gov/pubmed/27029915
http://dx.doi.org/10.1186/s12931-016-0351-6
Descripción
Sumario:In this pilot study, we examined associations between local interleukin (IL)-26, disease severity and biomarkers of Th2-mediated inflammation in a well-defined cohort of pediatric patients (14 years median age, 41 % females) with controlled (n = 28) or uncontrolled (n = 48) asthma. Sputum IL-26 protein concentrations (ELISA) reflected disease control in patients without local (low exhaled nitric oxide) or systemic (low blood eosinophils) signs of eosinophilic inflammation. Moreover, sputum-IL-26 concentrations correlated with those of blood neutrophils. Our study indicates that IL-26 is a potential biomarker of disease severity in pediatric asthma without signs of Th2-mediated inflammation.